A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma.|
Patients receive open-label ALRT1057 for 16 weeks, as tolerated. In the absence of unacceptable toxicity, patients may continue treatment indefinitely provided they continue to benefit from therapy and the study remains open and active.
Thirteen patients are treated initially. If at least one response is observed in these patients, up to 14 additional patients will be evaluated.